EF Hutton assumed coverage of Sonnet BioTherapeutics with a Buy rating and $6.70 price target. The firm made no change to its prior rating, price target or estimates.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SONN:
- Sonnet BioTherapeutics price target lowered to $12 from $14 at Chardan
- Sonnet BioTherapeutics announces FDA acceptance of IND for SB221 trial
- Sonnet BioTherapeutics reports Q3 EPS (13c) vs. ($1.82) last year
- Sonnet BioTherapeutics files to sell 5.15M shares of common stock for holders
- Sonnet BioTherapeutics announces $2.25M registered direct offering
